BioMark Diagnostics (BUX.CN) Stock Price
BioMark Diagnostics Price
Over the last 11 years BioMark Diagnostics grew revenue by 18.5% annually, reaching 59,787.00 CAD. For BioMark Diagnostics, the net margin of -2,470.8% is up versus -3,309.4% a few years ago.
BioMark Diagnostics stock price
BioMark Diagnostics business model & stock analysis
Frequently asked questions about BioMark Diagnostics
Converted at the current exchange rate, the BioMark Diagnostics share trades at 0.33 EUR (0.53 CAD).
The BioMark Diagnostics share (BUX.CN) is listed on 3 stock exchanges, including: Frankfurt (20B.F).
The revenue of BioMark Diagnostics is 59,787.00 CAD. This figure is based on current financial data and reflects the company's business performance.
The profit of BioMark Diagnostics is -1.48 M CAD. The net profit reflects the company's profitability after deducting all expenses.
The price-to-earnings ratio (P/E) of BioMark Diagnostics is currently -37.71. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the BioMark Diagnostics stock.
The price-to-sales ratio (P/S) of BioMark Diagnostics is currently 931.60. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the BioMark Diagnostics stock.
The Eulerpool Quality Score for BioMark Diagnostics is 3/10.
The ISIN of BioMark Diagnostics is CA09073K1084. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.
The WKN of BioMark Diagnostics is A12EKB. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.
The ticker of BioMark Diagnostics is BUX.CN. The ticker symbol is used to trade BioMark Diagnostics shares on the stock exchange.
BioMark Diagnostics stock
BioMark Diagnostics Peer Group
BioMark Diagnostics Ticker
BioMark Diagnostics FIGI
All fundamentals and in-depth analysis of BioMark Diagnostics
Our stock analysis for BioMark Diagnostics stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of BioMark Diagnostics. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.